We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.09% | 148.72 | 149.73 | 148.45 | 149.38 | 7,333,723 | 00:03:46 |
From May 2019 to May 2024
By Colin Kellaher
Amgen Inc. (AMGN) on Tuesday said a phase 3 study evaluating Kyprolis in combination with dexamethasone and Darzalex met its primary endpoint in patients with the blood cancer multiple myeloma.
The Thousand Oaks, Calif., biotechnology company said the study met its main endpoint of progression-free survival, resulting in a 37% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
Amgen said the combination also showed efficacy in key secondary endpoints, including overall response rate and overall survival.
Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement with Danish biotechology company Genmab A/S (GMAB).
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2019 08:05 ET (13:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
